AlphaFold 3 and AI-Driven Drug Discovery

AlphaFold 3 improved structure prediction accuracy by 50% over AlphaFold 2 and doubled accuracy for protein-ligand interactions, the core binding event in drug discovery. Published in Nature in 2024, it is now deployed across 50% of biotech organizations that have adopted AI, reducing time-to-target identification significantly. Companies like Insilico Medicine and Recursion Pharmaceuticals have advanced AI-designed compounds into clinical trials, a milestone no prior system achieved. The SPARK framework, tested on 5,400 patients across five tumor types, autonomously generates hypotheses—a capability that outperforms #8's manual processes. This integration collapses target-to-candidate timelines from years to months.